Evidence map›Paper›PMID 37990493›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.

Maria Beatrice Arasi, Gabriele De Luca, Laura Chronopoulou, Francesca Pedini, Eleonora Petrucci, Michela Flego, Annarita Stringaro, Marisa Colone, Luca Pasquini, Massimo Spada and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Maria Beatrice ArasiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Gabriele De LucaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Laura ChronopoulouDepartment of Chemistry, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy; Research Center for Applied Sciences to the safeguard of Environment and Cultural Heritage (CIABC) Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
Francesca PediniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Eleonora PetrucciDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Michela FlegoNational Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Annarita StringaroNational Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Marisa ColoneNational Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Luca PasquiniCore Facilities, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Massimo SpadaCenter of Animal Research and Welfare, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Valentina LulliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Maria Chiara PerrottaDepartment of Chemistry, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
George Adrian CalinTranslational Molecular Pathology, MD Anderson Cancer Center, Texas State University, 1515 Holcombe Blvd, Houston, TX 77030, USA; The RNA Interference and Non-coding RNA Center, MD Anderson Cancer Center, Texas State University, Houston, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Cleofe PalocciDepartment of Chemistry, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy; Research Center for Applied Sciences to the safeguard of Environment and Cultural Heritage (CIABC) Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy.
Mauro BiffoniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Federica FelicettiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Nadia FelliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Electronic address: nadia.felli@iss.it.
Istituto Superiore di Sanità · ITSapienza University of Rome · ITThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic melanoma poses significant challenges as a highly lethal disease. Despite the success of molecular targeting using BRAF

Indexed as

MelanomaMicroRNAsAnimalsCell Line, TumorHumansMicePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktSignal TransductionMicroRNAsMIRN126 microRNA, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktanti-CSPG4, drug resistancechitosandabrafenibmelanomametastasismicroRNAsmiR126nanoparticlesPI3K/AKT inhibitors

Identifiers

PMID37990493
PMCPMC10787166
OpenAlexW4388849561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.